Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence

Wiebke Pruessmann 1,8,10, Julie Rytlewski 2,10, James Wilmott 3,10, Martin C. Mihm Jr1, Grace H. Attrill3, Beatrice Dyring-Andersen1,9, Paul Fields 2, Qian Zhan1, Andrew J. Colebatch3,4, Peter M. Ferguson3,4, John F. Thompson 3,5, Klaus Kallenbach6, Erik Yusko2, Rachael A. Clark1, Harlan Robins2,7, Richard A. Scolyer 3,4,10 and Thomas S. Kupper 1,10*; 1Department of Dermatology and Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA. 2Adaptive Biotechnologies, Seattle, WA, USA. 3Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia. 4Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. 5Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. 6Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark. 7Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 8Present address: Department of Dermatology, University of Luebeck, Luebeck, Germany. 9Present address: Novo Nordisk Foundation Centre for Protein Research, University of Copenhagen, Copenhagen, Denmark. 10These authors contributed equally: Wiebke Pruessmann, Julie Rytlewski, James Wilmott, Richard A. Scolyer, Thomas S. Kupper.